1. Home
  2. FMAC vs KRRO Comparison

FMAC vs KRRO Comparison

Compare FMAC & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

FMAC

Future Money Acquisition Corporation Ordinary Shares

N/A

Current Price

$9.96

Market Cap

157.5M

Sector

Finance

ML Signal

N/A

Logo Korro Bio Inc.

KRRO

Korro Bio Inc.

HOLD

Current Price

$13.01

Market Cap

187.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FMAC
KRRO
Founded
N/A
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
157.5M
187.9M
IPO Year
2026
2019

Fundamental Metrics

Financial Performance
Metric
FMAC
KRRO
Price
$9.96
$13.01
Analyst Decision
Buy
Analyst Count
0
12
Target Price
N/A
$34.80
AVG Volume (30 Days)
6.0K
293.6K
Earning Date
N/A
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$6,392,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
181.46
52 Week Low
$9.95
$5.20
52 Week High
$10.02
$55.89

Technical Indicators

Market Signals
Indicator
FMAC
KRRO
Relative Strength Index (RSI) 45.32 50.21
Support Level $9.95 $10.02
Resistance Level N/A $14.78
Average True Range (ATR) 0.01 1.09
MACD -0.00 -0.12
Stochastic Oscillator 14.29 30.06

Price Performance

Historical Comparison
FMAC
KRRO

About FMAC Future Money Acquisition Corporation Ordinary Shares

Future Money Acquisition Corp is a blank check company formed for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities.

About KRRO Korro Bio Inc.

Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.

Share on Social Networks: